Keyphrases
Protease Inhibitors
100%
Bronchoscopy
100%
Intrathecal Midazolam
100%
Prolonged Sedation
100%
AIDS/HIV
66%
Length of Hospital Stay
33%
Antiretroviral Therapy
33%
Confidence Interval
16%
Hepatitis C Virus
16%
Viral Load
16%
Retrospective Cohort Study
16%
Academic Medical Centers
16%
Tertiary Care
16%
Relative Risk
16%
Demographic Characteristics
16%
Atazanavir
16%
Lopinavir
16%
Medical Records
16%
Patient Demographics
16%
Systematic Evaluation
16%
Altered Mental Status
16%
Antiretroviral Agents
16%
Hepatitis B Virus
16%
Sedative
16%
Co-infection
16%
Antiretroviral Regimens
16%
Respiratory Distress
16%
Concomitant Use
16%
Medication Records
16%
Procedural Sedation
16%
Medicine and Dentistry
Proteinase Inhibitor
100%
Bronchoscopy
100%
Midazolam
100%
Human Immunodeficiency Virus
66%
Antiretroviral Therapy
33%
Retrospective Cohort Study
16%
Drug Therapy
16%
Tertiary Care
16%
Medical Record
16%
Mental Health
16%
Hepatitis C Virus
16%
Antiretrovirus Agent
16%
Hepatitis B Virus
16%
Sedative Agent
16%
Demography
16%
Mixed Infection
16%
Respiratory Distress
16%
Atazanavir Plus Ritonavir
16%
Lopinavir/Ritonavir
16%
Pharmacology, Toxicology and Pharmaceutical Science
Proteinase Inhibitor
100%
Midazolam
100%
HIV
66%
Hepatitis C Virus
16%
Cohort Study
16%
Antiretrovirus Agent
16%
Hepatitis B Virus
16%
Respiratory Distress
16%
Mixed Infection
16%
Lopinavir Plus Ritonavir
16%
Atazanavir Plus Ritonavir
16%